STOCK TITAN

Sensus Healthcare Inc - SRTS STOCK NEWS

Welcome to our dedicated news page for Sensus Healthcare (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sensus Healthcare's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sensus Healthcare's position in the market.

Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) introduces its new 'Fair Deal Agreement' for SRT-100 Vision™ IG-SRT in one-on-one meetings, aiming to enhance customer value and establish a recurring revenue model. The company will engage with institutional investors at the 36th Annual Roth conference to discuss this program and recent achievements at the American Academy of Dermatology Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
conferences
-
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) successfully launched its new 'Fair Deal Agreement' for the SRT-100 Vision™ at the AAD 2024 Annual Meeting. The agreement expands access to their image-guided superficial radiotherapy technology for dermatology offices, generating record sales leads. The company's collaboration with CureRays enhances patient safety and regulatory compliance, positioning them as industry leaders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.58%
Tags
none
-
Rhea-AI Summary
Sensus Healthcare, Inc. (SRTS) announces fourth quarter revenues of $12.6 million, a three-fold increase sequentially, reflecting ongoing customer adjustment to macroeconomic conditions. The company introduces a recurring revenue model for the SRT-100 Vision™ (IG-SRT) to address dermatologist demand and ended the year with $23.1 million in cash and cash equivalents, and no debt. The company also showcased the full line of SRT systems for treating non-melanoma skin cancer at the Fall Clinical 2023 dermatology conference and engaged CureRays to provide oversight and supervision for Sensus’ dermatology customers involved with the recurring revenue model and to ensure patient safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.3%
Tags
earnings
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) has been issued a new patent by the USPTO for a radiotherapy mobile and wireless device workflow management system. The patent covers systems and methods for treating patients with a radiotherapy system combining high-frequency ultrasound and optical imaging data. This technology is a treatment-planning system that fuses a radiation therapy device with a high-frequency ultrasound (the SRT-100 Vision) to guide clinicians in creating treatment plans. The patent also covers scheduling patient appointments, detecting medical equipment status, and communicating information on status to a service engineer. This new patent adds to Sensus Healthcare's valuable intellectual property portfolio and ensures protection for their innovative products for years to come.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
-
Rhea-AI Summary
Sensus Healthcare, Inc. announces a collaboration with CureRays, a radiation oncology specialist organization, to research new indications for Sensus' superficial radiotherapy (SRT and IG-SRT) to include inflammatory diseases. CureRays will also provide oversight and supervision for Sensus' dermatology customers to ensure patient safety and regulatory compliance. The collaboration aims to broaden the market for Sensus' products, starting with arthritis. CureRays is led by Dr. Mohammad K. Khan and Dr. Clayton Hess, who are focused on radiation treatments for patients, radiation consulting for physicians, and the conduct of clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.72%
Tags
none
-
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) announces the retirement of Samuel O'Rear from the Board of Directors and the appointment of Michael J. Sardano as a Director. The company expresses gratitude to O'Rear for his dedicated service and welcomes Sardano, highlighting his contributions to the company's milestones. O'Rear reflects on his 50 years of professional experiences in the healthcare industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on February 8, 2024, to discuss the financial results for the fourth quarter and full year 2023, along with a business update and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
conferences earnings
-
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) announces preliminary unaudited financial results for the three and 12 months ended December 31, 2023. The company expects to report revenue for the fourth quarter of 2023 of more than $12 million, with full-year revenue expected to exceed $23 million. They also achieved their guidance to ship more than 60 SRT systems during 2023. The company experienced a strong uptick in business during the fourth quarter despite customer impact from inflation and interest rates in the first three quarters of 2023. Sensus Healthcare plans to announce full financial results and hold an investment community conference call on February 8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.32%
Tags
none
-
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) announces financial results for the three and nine months ended September 30, 2023, reflecting lower revenues due to seasonality and macroeconomic conditions. The company reported revenues of $3.9 million, net loss of $1.5 million, and $20.5 million in cash and cash equivalents. The financial results were impacted by lower superficial radiotherapy (SRT) unit sales and lower sales to a large customer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.41%
Tags
earnings
Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on November 9, 2023, at 4:30 p.m. Eastern time to discuss the financial results for Q3 2023. The call will include a business update and discussion on recent and upcoming milestones. Participants can pre-register for the call to receive a unique dial-in number. The call will be webcast live and a telephone replay will be available until December 9th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
conferences earnings
Sensus Healthcare Inc

Nasdaq:SRTS

SRTS Rankings

SRTS Stock Data

62.30M
13.07M
21.39%
17.07%
0.4%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Boca Raton

About SRTS

sensus healthcare, inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancer and keloids. sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (srt), which is a result of over a decade of dedicated research and development activities. sensus has successfully incorporated the srt therapy into its portfolio of treatment devices: srt-100™ and srt-100 vision™. srt technology effectively and safely treats oncological and non-oncological skin conditions. for more information, visit http://www.sensushealthcare.com.